Abstract Library

#3726 Inflammation based index and tumor heterogeneity on pretherapeutic 68Ga DOTATOC PET/CT predict outcome in midgut neuroendocrine tumor patients treated with 177Lu-oxodotreotide

Introduction: Peptide receptor radionuclide therapy with 177Lu oxodotreotide (LuPRRT) is a standard treatment for the management of patients with inoperable metastatic well-differentiated neuroendocrine tumors of the midgut (iNET). As LuPRRT becomes widely used for a heterogeneous population of NET patients, practical predictive biomarkers are needed. Inflammation based index (IBI) derived from serum C reactive protein and albumin is associated with progression free survival (PFS) and overall survival (OS) in patients with PRRT for NETs. Ga-68 DOTATOC PET/CT (DOTAPET) assessment of lesion heterogeneity was predictive for response to PRRT.

Conference:

Presenting Author: Vija L

Authors: Vija L, Dierickx L, Kanoun S, Texier J, Terroir M,

Keywords: LuPRRT, GaDOTA PET/CT, neuroendocrine tumor, outcome,

#3246 Baseline albumin and neutrophil-to-lymphocyte ratio as predictive biomarkers of response to platinum-based therapy in patients with highly proliferative neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NECs) with ki-67/MIB1>55% show different responses to platinum-based therapy. Loss of Rb protein and KRAS mutation are markers of response, but it is unknown whether also clinical factors may have a predictive role.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Colombo E

Authors: Colombo E, Manca P, Prinzi N, Torchio M, Corti F,

Keywords: neuroendocrine carcinoma, albumin, neutrophil-to-lymphocyte ratio, neutropenia, platinum-based therapy, predictive biomarker, clinical biomarker, NECs,

#3172 Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE following liver directed therapy (LDT) in neuroendocrine tumors (NETs): Hepatotoxicity and impact on progression-free survival (PFS)

Introduction: PRRT (Lu-DOTATATE) and LDT (e.g. hepatic artery embolization) are commonly used in treating liver dominant NETs. Hepatotoxicity from PRRT in the setting of metastatic disease and prior liver-directed therapy is an important consideration. There is a concern for hepatotoxicity in patients receiving PRRT based on the literature, but there is limited data on patients who may have had a prior liver injury from LDT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Halfdanarson T, Johnson G, Hobday T, Young J,

Keywords: hepatotoxicity, PRRT (LU-DOTATATE), liver targeted therapy, progression-free survival, NEN, NET,

#2690 Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report

Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Qi Z, Zhang Y, Li Y, Wang C, Wang X,

Keywords: neuroendocrine carcinoma, albumin-bound paclitaxe,

#2147 Nutritional Assessment and Vitamin Deficiencies in Patients with NETs

Introduction: As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lim S, Reynolds M, Rees D, Chaudhry R, Blackhouse J,

Keywords: Nutrition, Dietetics, Malnutrition, Vitamin Deficiency, Screening,